Citius Oncology (CTOR) news
Recent news
Citius Oncology expands board with appointment of independent director Jonathan Peri
AInvest Wire · Aug 12, 2026Citius Oncology reports strong commercial momentum for its cancer treatment
Citius Oncology, Inc. (NASDAQ: CTOR) has reported strong commercial momentum for its FDA-approved cancer treatment, LYMPHIR™ (denileukin diftitox-cxdl), since its U.S. launch in December 2025. The company generated $3.9 million in revenue during the first quarter of fiscal 2026, marking its first…
AInvest Wire · Aug 5, 2026ImportantTesla: No concrete plan to mass-produce robots at Shanghai Gigafactory
AInvest Wire · Apr 20, 2026IAEA: Team at Ukraine's ZNPP reports challenges with cooling water availability; off-site power must be fully resolved before reactor restarts.
IAEA: Team at Ukraine's ZNPP reports challenges with cooling water availability; off-site power must be fully resolved before reactor restarts. The International Atomic Energy Agency (IAEA) has reported significant challenges in ensuring the cooling water supply and off-site power for Ukraine's…
AInvest Wire · Jun 19, 2025UK-France power interconnector outage extended by one day
UK-France power interconnector outage extended by one day LONDON (Reuters) - The UK-France power interconnector project, a critical link in the European power grid, has seen its completion date extended by one day, according to recent updates from the European Investment Bank (EIB). The project,…
AInvest Wire · Jun 19, 2025Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.